Sugemalimab is the world’s first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy The data showed that sugemalimab demonstrated a statistically significant and clinically meaningful improvement in the Blinded Independent CentralContinue Reading

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 2 study in Chinese patientsContinue Reading

SHANGHAI, Sept. 17, 2021 /PRNewswire/ — Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement with Eyenovia, Inc. (NASDAQ: EYEN) to include a third asset, MydCombi™, for development and commercialization in Greater China (mainland China, Hong Kong, MacauContinue Reading

Collaboration consolidates Everest’s leadership in the renal space Everest Medicines will pay Sinovent and SinoMab USD $12 million in upfront and up to $549 million in total development, regulatory, and commercial milestone payments SHANGHAI, Sept. 17, 2021 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”) announced today that it has entered intoContinue Reading

International CRM software provider, Really Simple Systems, releases a new integration with Microsoft 365 for contacts and calendars. PETERSFIELD, England, Sept. 17, 2021 /PRNewswire/ — Leading cloud software developer and vendor, Really Simple Systems, has launched of a new integration between its popular CRM and Microsoft 365, enhancing its platformContinue Reading

Pre-clinical data exploring the in vitro and in vivo efficacy of BBT-176 will be disclosed via an ePoster at the ESMO Congress 2021 Patient dosing for the phase 1/2 clinical study of BBT-176 was initiated in April 2021…the topline data of the first-in-human, dose escalation study is expected to beContinue Reading

Autumn is a Spectacular Time to See Glacier National Park Autumn is a Spectacular Time to See Glacier National ParkContinue Reading